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Abstract
Background: Arterial hypertension (AH) induces cardiac hypertrophy and reactivation of ‘‘fetal’’ gene expression. In rodent
heart, alpha-Myosin Heavy Chain (MyHC) and its micro-RNA miR-208a regulate the expression of beta-MyHC and of its
intronic miR-208b. However, the role of aldosterone in these processes remains unclear.
Methodology/Principal Findings: RT-PCR and western-blot were used to investigate the genes modulated by arterial
hypertension and cardiac hyperaldosteronism. We developed a model of double-transgenic mice (AS-Ren) with cardiac
hyperaldosteronism (AS mice) and systemic hypertension (Ren). AS-Ren mice had increased (x2) angiotensin II in plasma and
increased (x2) aldosterone in heart. Ren and AS-Ren mice had a robust and similar hypertension (+70%) versus their controls.
Anatomical data and echocardiography showed a worsening of cardiac hypertrophy (+41%) in AS-Ren mice (P,0.05 vs Ren).
The increase of ANP (x 2.5; P,0.01) mRNA observed in Ren mice was blunted in AS-Ren mice. This non-induction of
antitrophic natriuretic peptides may be involved in the higher trophic cardiac response in AS-Ren mice, as indicated by the
markedly reduced cardiac hypertrophy in ANP-infused AS-Ren mice for one month. Besides, the AH-induced increase of
ßMyHC and its intronic miRNA-208b was prevented in AS-Ren. The inhibition of miR 208a (275%, p,0.001) in AS-Ren mice
compared to AS was associated with increased Sox 6 mRNA (x 1.34; p,0.05), an inhibitor of ßMyHC transcription.
Eplerenone prevented all aldosterone-dependent effects.
Conclusions/Significance: Our results indicate that increased aldosterone in heart inhibits the induction of atrial natriuretic
peptide expression, via the mineralocorticoid receptor. This worsens cardiac hypertrophy without changing blood pressure.
Moreover, this work reveals an original aldosterone-dependent inhibition of miR-208a in hypertension, resulting in the
inhibition of b-myosin heavy chain expression through the induction of its transcriptional repressor Sox6. Thus, aldosterone
inhibits the fetal program and increases cardiac hypertrophy in hypertensive mice.
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Introduction
Cardiac hypertrophy (CH) is a well-known consequence of
chronic arterial hypertension. If untreated, hypertension leads to
profound changes of the structural and functional properties of the
cardiovascular system, ultimately leading to heart failure. CH is
mainly due to hypertrophy of cardiomyocytes that is likely induced
by both mechanical and hormonal factors, such as angiotensin II
(AngII) and aldosterone [1]. Aldosterone controls the renal sodium
reabsorption, thereby playing a major role in the control of plasma
volume. In addition, it has emerged in the last years that elevation
of plasmatic concentration of aldosterone which occurs in patients
with heart failure, is a key-factor of cardiac remodeling [2,3,4] and
worsening of cardiac properties. The inhibitors of the aldosterone
receptor (mineralo-corticoid receptor, MR) have successfully been
used in patients with heart failure [5] and are now approved in the
clinical treatment of heart failure. However, the mechanisms of the
deleterious consequences of aldosterone on cardiac functional
properties are not totally understood. Increasing evidence suggests
that aldosterone may be a trigger for CH independently of its role
in regulation of salt-water balance and blood pressure [6,7,8].
To prevent cardiac failure, it is necessary to identify precisely
the molecules that regulate the hypertrophic program. In
hypertension-induced CH, cardiomyocytes undergo important
molecular changes that initially allow the adaptation to increased
wall stress. These changes involve the re-expression of a fetal
genetic program identified by the induction of natriuretic peptides
(NPs), b-myosin heavy chain (b-MyHC), and a- skeletal actin [1].
Cardiac hypertrophy is in part activated by multiple signalling
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38197molecules: the calcineurin phosphatase, the serine/threonine
protein kinase AKT, the extracellular regulated MAP kinase
(ERK), and several transcription factors like NFAT (nuclear factor
of activated T-cells), GATA4, MEF2 (myocyte enhancer factor 2),
SRF (serum response factor) and p-CREB (phosphorylated
cAMPresponse element binding) acting on different target genes
[9,10]. In addition many genes are under fine post-transcriptional
control by microRNAs (miRNAs). The Myh6 gene encodes a-
MyHC and the intronic miR-208a. Similarly, the Myh7 gene
encodes b-MyHC and miR-208b. MiR-208a inhibits the Sox6
factor, which inhibits the expression of both b-MyHC and miR-
208b [11,12].
Table 1. Anatomy and cardiac function.
Groups WT AS Ren AS-Ren
n = 6n = 6n = 7n = 6
Systolic blood pressure (mmHg) 86658 0 621 3 9 64**
£ 14169**
£
LVPW (mm) 1.160.07 1.260.1 1.4360.04**
£ 1.460.06*
£
IVSd (mm) 1.160.06 1.160.02 1.460.05*
£ 1.460.06*
£
SF (%) 55.260.7 58.360.8* 58.361.6 61.461.3*
Hormones (plasma)
Angiotensin II (fM) 57636 8 648 8 62***
£ 11264***
£$
Aldosterone (nM) 0.760.02 0.7460.04 0.760.02 1.660.1***
£$
Hormones (heart)
Aldosterone (nM) 8.660.5 14.960.4** 860.4 20.460.7***
£$
mRNAs (heart)
ACE (A.U.) 0.6460.07 0.5460.1 0.7760.06 0.9260.09*
£
Anatomy
BW (g) 2960.8 30623 0 60.3 3160.9
HW (mg) 128671 4 9 621 5 5 681 9 5 61**
$
HW/BW (mg/g) 4.360.2 4.860.4 5.260.2* 6.260.2**
£$
Abbreviations: LVPW: Left Ventricular Posterior Wall thickness; IVSd: InterVentricular Septum thickness in diastole; SF: Shortening Fraction; BW: Body Weight; HW: Heart
Weight.
*p,0.05.
**p,0.01.
***p,0.001 vs WT.
£p,0.05 vs AS.
$p,0.05 vs Ren.
doi:10.1371/journal.pone.0038197.t001
Figure 1. Cardiac hyperaldosteronism inhibits hypertension-induced ANP expression. The expression of ANP was analysed in 9 month-
old mice by quantitative RT-PCR analysis: (A) in ventricles of control mice (WT, AS), of Ren mice and AS-Ren mice untreated or treated with
eplerenone (100 mg/kg/day) for 30 days, (B) in NMCM stimulated by 10
25 M AngII in the presence or absence of aldosterone (10
29 Mo r1 0
27 M)
(data are mean of 3 independent experiments). Abbreviations: WT: wild-type mice, AS: aldosterone-synthase overexpressing mice, R: renin-
overexpressing mice, ASR: AS and R crossed-mice (see details in methods); Aldo: aldosterone; AngII: angiotensin II; Eple: eplerenone treatment; AU:
Arbitrary Units; n=10–12/group. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0038197.g001
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e38197This work aimed to study the role of aldosterone in the
mechanisms and signalling pathways regulating CH in transgenic
hypertensive mice. Our results indicate that elevated levels of
aldosterone in the heart inhibit NPs and b-MyHC expression
through original mechanisms.
Materials and Methods
Animals
All experimentations were conducted in agreement with
accepted standards of animal care, as outlined in the NIH Guide
for the Care and Use of Laboratory Animals and were approved
by the local ethics committee (Ethics Committee for Animal
Experimentation Lariboisiere-Villemin of the School of Medicine
Paris 7, Paris, France). The local ethics committee specifically
approved this study (nu2010-12-02). Double transgenic mice (AS-
Ren) were created by crossing RenTgKC female with AS male
mice. RenTgKC mice backcrossed in the genetic background 129
SV overexpress a synthetic renin cDNA (Ren-2 and Ren-1d genes)
in liver and develop early a sustained hypertension [13,14]. AS
male mice were raised by our laboratory in a FVB background to
over-express the aldosterone-synthase (AS) gene in cardiomyo-
cytes. To this end, the AS gene expression was under the control of
an alpha-myosin heavy chain promoter sequence inserted in the
transgene. AS mice have a normal cardiac phenotype despite a 2-
fold higher intracardiac aldosterone concentration [15], except a
BKCa channel dependent coronary dysfunction [16]. AS-Ren
mice of F1 generation were used in all experiments. All mice were
viable and only male were used. WT and AS littermates were used
as controls. 6 or 9 month-old mice were sacrificed with an
overdose of pentobarbital. The hearts were arrested in diastole by
an intravenous injection of saturated KCl, they were quickly
removed, weighed and cut transversely at the ventricles equator.
The upper parts of the heart were mounted, frozen in isopentane
precooled with liquid nitrogen, and kept at 270uC until use, as
previously described [17].
Figure 2. Cardiac hyperaldosteronism inhibits hypertension-induced b-MyHC expression. The expression of b-MyHC was analysed in
9 month-old mice by: (A) quantitative RT-PCR in ventricles of control mice (WT, AS), of Ren mice and AS-Ren mice untreated or treated with
eplerenone (100 mg/kg/day) for 30 days, (B) quantification of b-MyHC and total MyHC protein levels in ventricles after immunoblot (representative
signals are shown), (C) quantitative RT-PCR in NMCM stimulated by 10
25 M AngII in the absence or presence of aldosterone (data are mean of 3
independent experiments), Abbreviations and symbols as in Figure 1. n=10–12/group.
doi:10.1371/journal.pone.0038197.g002
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The mineralocorticoid receptor (MR) antagonist eplerenone
(Tocris, Bristol, UK) was administered in food to mice at 100 mg/
kg/day as previously described [18], in 6 and 8 month-old mice
for 10 and 30 days before sacrifice, respectively.
ANP Infusion
After isoflurane (2%) anaesthesia, 8-month old Ren and AS-Ren
mice were implanted subcutaneously with osmotic minipumps
(Alzet, 2004) delivering 50 mg/kg/day ANP (Sigma-Aldrich, Saint
Louis, MO) for 1 month. These animals were thus named ‘‘9-
month old mice’’ in the text. Since sham pump implantation was
devoid of any effect on blood pressure and cardiac hypertrophy,
non-implanted Ren and AS-Ren mice were used as controls to the
ANP-infused mice.
Blood Pressure
Systolic blood pressure was measured in unanesthetized mice by
the tail-cuff method (Kent Scientific Corporation, Torrington,
USA) after daily accustomization during 2weeks before measure-
ments. Only animals that did not display signals of stress and that
showed stable and reproducible values of blood pressure for at
least three consecutive days were considered for blood pressure
measurements. Ten measurements from each mouse were taken at
two minutes intervals then a mean value was determined.
Echocardiography
Echocardiographies were performed on Ketamin (Virbac,
100 mg/Kg) anesthetized animals, in a blinded fashion using a
GE Vivid-7 machine (General Electric Medical Systems, Paris,
France) equipped with an 8–14 MHz linear transducer. The
thickness of the left ventricle LV and fractional shortening were
measured as in [19].
Aldosterone and AngII Measurements
Blood was collected during the sacrifice and plasma was isolated
by centrifugation. Aldosterone and AngII plasmatic and cardiac
concentrations were measured by radioimmunoassay (RayBiotech
company, Cayman chemical company, respectively) according to
the manufacturer’s instructions.
Immunofluorescence Analysis
Immunostaining was performed on cryostat sections fixed
with 4% PFA. Identification of cardiomyocytes was performed
with mouse vinculin antibody (Sigma Aldrich, Saint Quentin
Fallavier, France, 1/250), as previously described [18]. A Leica
Camera equipped with a fluorescent Leica DMR (Leica
Microsys tems, Rueil Malmaison, France) allowed the fluores-
cence detection.
RNA Extraction and PCR
RNA was isolated using the RNeasy Mini Kit (Qiagen,
Courtaboeuf, France) according to the manufacturer’s instruc-
tions and reverse transcribed using Ready-to-go You-Prime
First-Strand Beads kit (GE Healthcare) with 2 mg of RNA and
0.5 mg of oligo dT (Invitrogen, Saint Aubin, France). Finally,
real-time amplification was performed with Mastercycler
Realplex2 (Eppendorf, Le Pecq, France) using the MESA
BLUE qPCR MasterMix Plus for SYBRH Assay No ROX
(Eurogentec, Angers, France). mRNAs data were normalized by
the abundance of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA for each sample and expressed as the relative
change compared with the control sample. Primers are listed in
Supplemental Table S1.
MicroRNAs Analysis
Total RNA was extracted from frozen tissue using the mirVana
kit (Life Technologies, Saint Aubin, France) according to the
manufacturer’s instructions without enrichment for small RNAs.
Potential genomic DNA contamination was eliminated using
DNA-free kit (Qiagen). RNA (150 ng) was used per 20-mL reaction
to generate cDNA using the miScript reverse transcription kit
(Qiagen). Quantitative RT-PCR was performed using 30 ng
cDNA with specific miScript primer sets and miScript SYBR
Green PCR kit (Qiagen). Quantitative measurements of miRNA
levels were normalized for isolation efficiency using a mix of
3 spiked-in synthetic Caenorhabditis elegans miRNAs (Qiagen),
lacking sequence homology to human miRNAs, as described
previously [20]. Oligonucleotides were spiked into the samples
during RNA isolation after tissue incubation with the provided
lysis solution. In addition, results were corrected using the
endogenous miR-16.
Figure 3. Effect of aldosterone on CREB expression. (A):
quantitative RT-PCR analysis of CREB in 9 month-old mouse ventricles
and (B) representative immunoblots of p-CREB, CREB and GAPDH levels
in ventricle protein extracts. Abbreviations and symbols as in Figure 1.
doi:10.1371/journal.pone.0038197.g003
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Heart tissue was homogenized in a lysis buffer (50 mM Tris
HCl pH 7.4, 5 mM EDTA, 100 mM NaCl, 0.2 mM sodium
vanadate, 50 mM sodium fluoride, 40 mM b-glycerophospha-
tase), with 1% Triton 6100 for myofibrils preparation. Lysates
were incubated 1 h on ice before clearing by centrifugation
(12000 rpm, 4uC, 20 min). Pellets dissolved in 1% SDS were
quantified with Pierce BCA Protein Assay Kit (Pierce Biotech-
nology, USA). Proteins (0.4 mg) were fractionated on a 4–20%
polyacrylamide gel (Invitrogen) and transferred onto nitrocellu-
lose membrane. After blocking, nitrocellulose blots were
incubated with mouse anti-b-MyHC (Sigma-Aldrich, Saint
Quentin Fallavier, France, 1/2000) or mouse anti-MyHC
(Sigma-Aldrich, 1/5000) overnight at 4uC. A secondary
antibody coupled to horseradish peroxidase (1/5000, Sigma)
was then applied for 2 h at 21uC and detection was performed
with enhanced chemiluminescence (ECL Plus, GE Healthcare).
Chemiluminescence was measured using a LAS 3000 and
MultiGauge V2.02 software (Fuji, Courbevoie, France).
In vitro Studies
Isolation of neonatal mouse cardiomyocytes (NMCM) was
performed as described [21]. After 72 h of culture, plated
cardiomyocytes were starved (0.2% Serum) and pre-treated with
aldosterone (10
29 or 10
27 M) overnight (37uC, 5% CO2). Then,
10
25 M AngII was added and RNA was extracted after 24 h.
Statistical Analysis
All results are expressed as means 6 SEM. Following ANOVA
analysis, a Student’s t test with Bonferroni correction was
performed except otherwise indicated. p,0.05 was considered as
statistically significant. The significance is indicated by a horizon-
tal line between the two groups of interest.
Results and Discussion
Effects of Cardiac Hyperaldosteronism and/or
Hypertension on Cardiac Hypertrophy
The study was done on 6 and 9 month-old mice in order to
study the development of cardiac hypertrophy. Blood pressure was
already increased at 6 month of age in Ren and AS-Ren mice, and
further increased at 9 months when systolic pressure reached
+62% and +76% in Ren and AS-Ren mice when compared to
WT and AS mice, respectively (Table 1). Plasmatic AngII
concentration was higher in Ren mice and further enhanced in
AS-Ren. The cardiac ACE mRNA level and plasma aldosterone
concentration were increased in AS-Ren mice only. Cardiac
aldosterone concentration was elevated in AS mice as already
observed in this strain [15], and its level was enhanced in AS-Ren
mice (Table 1). The increase in plasmatic AngII level in AS-Ren
relative to Ren might be secondary to the aldosterone-induced
ACE upregulation in the heart [22,23]. These results illustrate the
existence of a vicious cycle between peripheral renin-angiotensin
system and cardiac aldosterone synthase, which likely results in
both an increase of AngII plasma level and a leak of cardiac
aldosterone in the blood stream. Both the echocardiographic (Left
Ventricular Posterior Wall and diastolic InterVentricular Septum
thicknesses) and anatomic (heart weight/body weight ratio) data of
hypertensive mice indicated signs of concentric cardiac hypertro-
phy. However, the cardiac hypertrophy of AS-Ren mice was
markedly higher than that of Ren mice (+20% vs. Ren mice;
p,0.05) (Table 1, Supplemental Figure S1). This difference of
hypertrophic response despite the similar levels of hypertension in
Ren and AS-Ren mice indicates that the pro-trophic effect of
aldosterone is potentiated by hypertension. This result is in
agreement with experimental [24] and clinical [25,26] studies
using MR antagonists. This is also in line with the strong
correlation between left ventricle (LV) mass index and serum
Figure 4. ANP infusion reduces cardiac hypertrophy. (A): systolic blood pressure and (B) heart weight/body weight ratio (HW/BW) of 9 month-
old Ren and AS-Ren mice treated with ANP for 1 month. Abbreviations and symbols as in Figure 1. n=5–6/groups.
doi:10.1371/journal.pone.0038197.g004
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[27,28]. The evidence of a trophic effect of aldosterone was
strengthened by the results of an eplerenone treatment, which
decreased significantly the AS-Ren heart weight/body weight ratio
(210% vs. non treated AS-Ren mice) without any change of blood
pressure after 10 days (Supplemental Figure S2). Furthermore, a
partial prevention of cardiac hypertrophy by 1month of
eplerenone treatment in AS-Ren mice was detected by the
echocardiographic (LVPW) and anatomical data (HW/BW)
(Supplemental Table S2). This result was in agreement with the
very recent data of Fraccarollo et al showing that cardiomyocyte-
specific MR ablation prevents the development of cardiac
hypertrophy after myocardial infarction [29].
Hyperaldosteronism Regulates Fetal Genes Reexpression
in Heart
As expected in such a hypertension model, the expression of the
fetal genes (Nppa and Myh7, coding for ANP and b-MyHC,
respectively) was robustly induced in Ren mice (x2.5, x2.2;
p,0.001 respectively; Figures 1 and 2). Interestingly, this
induction was markedly inhibited in AS-Ren mice (260%,
243% vs. Ren; p,0.05). Similarly to its mRNA, the b-MyHC
protein level was increased in Ren and AS-Ren hypertensive mice
(Figure 2B). However, this increase was partly blunted by cardiac
hyperaldosteronism (240% vs. Ren mice; p,0.05), in line with
transcriptional analysis. These results contrast with others
suggesting that aldosterone favours the cardiac fetal gene
Figure 5. Effect of combined cardiac aldosterone and hypertension on cardiac miR-208 and Sox6 expression. (A): scheme of the
interplay of miR-208a and -208b on the regulation of Myh7 expression in hypertensive heart, as drawn from literature data. (B-D): quantitative RT-PCR
analysis of miR-208a, Sox6 and miR-208b expression in 9 month-old WT, AS, R and AS-R mice and in AS-R eplerenone treated mice (100 mg/Kg/day)
for one month. (E): quantitative RT-PCR analysis of Sox6 expression in NMCM stimulated by 10
25 M AngII in the presence or absence of aldosterone
(10
29 Mo r1 0
27 M). Abbreviations and symbols as in Figure 1; HT: hypertension; n=10–14/group.
doi:10.1371/journal.pone.0038197.g005
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This discrepancy might be due to an increased type I angiotensin
receptor activity in vivo [31] or to experimental conditions that
would differ for aldosterone concentration or time points. In
cultured NMCM, aldosterone alone inhibited the expression of b-
MyHC mRNA (Figure 2C). When the cardiomyocytes were
stimulated with AngII, aldosterone dose-dependently inhibited the
expression of ANP and b-MyHC mRNAs (Figures 1B and 2C). In
vivo, the aldosterone effect was reversed in presence of eplerenone
(Figures 1A and 2A). Altogether, these data indicate that
aldosterone inhibits b-MyHC and NPs expression via the MR
signaling pathway.
Act1 encoding a-skeletal actin is one to the fetal genes up-
regulated during an hypertension-induced cardiac hypertrophy
[32]. Its expression requires the serum response factor (SRF)
associated with GATA4 [33]. Of note, the mRNA expression of
Act1 and SRF increased in a similar manner in both Ren and AS-
Ren groups (Supplemental Figure S3A-B), indicating a reactiva-
tion of SRF pathway in the hypertensive hearts independently of
aldosterone.
Implication of p-CREB Signaling in Aldosterone Inhibition
of ANP Expression
The cAMP-CREB pathway, which is involved in the transcrip-
tion of Nppa [34], is inhibited by aldosterone [35,36]. We observed
that aldosterone inhibited CREB transcription and phosphoryla-
tion in AS-Ren hearts (Figure 3), suggesting that aldosterone
impedes ANP transcription by inhibiting CREB activation.
Natriuretic peptides (NPs) being known to counteract the
development of hypertrophic process [37], the observations that
eplerenone treatment upregulated NPs and inhibited the hyper-
trophic process in AS-Ren prompted us to test if ANP might
reverse the development of cardiac hypertrophy in these mice.
Thus, ANP minipumps were implanted in 8 month-old AS-Ren
mice for one month. This chronic ANP infusion had no effect on
blood pressure in any group (Figure 4A), but it decreased the
cardiac hypertrophy only in AS-Ren mice whereas it had no
action on the heart weight of Ren animals (Figure 4B). Conse-
quently, it emerged that aldosterone worsened the development of
cardiac hypertrophy through a MR-dependent inhibition of ANP
expression.
Regulation of miRNAs Expression by Cardiac
Hyperaldosteronism Combined with Arterial
Hypertension
As outlined in the Introduction section and in Figure 5A, the
expression of Myh7 is controlled by miR-208a and the Sox6
transcription factor [11,12]. As expected in the experimental
groups, the expression of miR-208b (x3.8; p,0.01 vs. control
mice; Figure 5D) mirrored that of b-MyHC mRNA (Figure 2A).
Indeed, the maintained expression of miR-208a and the strong
induction of miR-208b mRNA in Ren mice (Figure 5B and C) was
in agreement with the low Sox6 mRNA level (250%, p0.05 vs.
control mice, Figure 5D). Interestingly, in AS-Ren mice the
increase of miR-208b transcription that was observed in Ren mice
was significantly inhibited (260% vs. Ren). Thus, the maintained
level of Sox6 transcription observed in AS-Ren mice (+50%;
p,0.05 vs. Ren) is likely involved in Myh7 repression. The specific
inhibition of miR-208a observed in AS-Ren mice (258% vs. WT
and Ren mice; 235% vs. AS mice) (Figure 5B) is consistent with
the Sox6 and a-MyHC mRNA profile. In addition, aldosterone
increased Sox6 expression in NMCM with or without AngII
(Figure 5E). Hence, the cardiac hyperaldosteronism inhibits miR-
208a expression, allowing a sustained Sox6 expression, which in
turn inhibits the Myh7 transcription.
Furthermore, in AS-Ren mice the expression profiles of miR-
208a, Sox6, miR-208b (Figure 5 A, C and B) and of b-MyHC
(Figure 2D) were reversed by eplerenone (+250%, 250%, +221%,
+242%, respectively, vs. untreated AS-Ren) indicating involve-
ment of the MR pathway.
Conclusions
Using combined hypertension and hyperaldosteronism and
both in vivo and in vitro studies, it is demonstrated for the first
time that aldosterone, via its mineralocorticoid receptor, represses
the expression of ANP and ß-MyHC in a pathological context,
thereby amplifying cardiac hypertrophy. Our data provide
important information for the understanding of aldosterone-MR
implication in the cardiac hypertrophy machinery.
Supporting Information
Figure S1 Aldosterone worsens cardiac hypertrophy in
hypertension. Representative cardiomyocyte hypertrophy as-
sessed by vinculin immunolabeling on LV sections of 9 month-old
control (WT, AS) and hypertensive (R, AS-R) mice. External
membrane of cardiomyocytes is highlighted in red to show the
increase of cell size in hypertension. Fluorescent area (*) indicates
en face intercalated disc. Bar: 100 mm. Abbreviations: WT: wild-
type mice, AS: aldosterone-synthase overexpressing mice, R:
renin-overexpressing mice, ASR: AS and R crossed-mice.
(TIF)
Figure S2 Prevention of aldosterone effects by epler-
enone in 6 month-old AS-Ren mice. (A): systolic blood
pressure and (B) Heart weight/body weight ratio (HW/BW) of
6 month-old Ren and AS-Ren mice treated with eplerenone (Eple,
100 mg/Kg/day) for 10 days. In panel A, the horizontal dotted
line represents the systolic blood pressure in normotensive mice.
(C-E): quantitative RT-PCR analysis of ANP, b-MyHC, miR-
208a, Sox6 and miR-208b expression in 6 month-old AS-Ren
eplerenone-treated and untreated mice. Abbreviations: HW/BW:
heart weight/body weight ratio; R: renin-overexpressing mice,
ASR: AS and R crossed-mice; AU: Arbitrary Units. Eple:
eplerenone. n=6–8.
(TIF)
Figure S3 Effect of AngII and aldosterone on cardiac
phenotype. RT-PCR quantification of a skeletal actin, SRF, a-
MyHC, BNP and cardiac a-actin mRNAs level in 9 month-old
mice. (6 - 10 in each group). Abbreviations: WT: wild-type mice,
AS: aldosterone-synthase overexpressing mice, R: renin-overex-
pressing mice, ASR: AS and R crossed-mice; AU: Arbitrary Units.
(TIF)
Table S1 Sequence of primers used for PCR.
(DOC)
Table S2 Effect of eplerenone on hemodynamic and
anatomical indexes of 9-month old mice.
(DOC)
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